New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs GHRP-6

PNC-27 vs GHRP-6

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Growth Hormone Peptides
GHRP-6
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
GHRP-6 is the original synthetic GH-releasing peptide and a potent ghrelin receptor agonist. It produces strong GH pulses but is notorious for a significant hunger surge 30–45 minutes post-injection. This hunger side effect makes it less preferred than Ipamorelin or GHRP-2 for most protocols but can be useful in patients with appetite deficiency.
Half-Life
Not well established; estimated minutes to hours
15–60 minutes
Admin Route
Intravenous (research), Intraperitoneal (research)
SubQ, Intranasal
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
100–300 mcg
Frequency
Not established for human use
2–3 times daily
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Strong GH stimulation
  • Elevated IGF-1
  • Muscle growth and recovery support
  • Potential anti-inflammatory effects at GI level
  • Useful for patients with appetite deficiency or cachexia
  • Enhanced recovery from training
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Intense hunger surge (30–45 min post-injection)
  • Water retention
  • Elevated cortisol (modest)
  • Elevated prolactin (modest)
  • +2 more
Stacks With